Effectiveness of leukotriene receptor antagonists in the treatment for atopic pathology in children
https://doi.org/10.51523/2708-6011.2020-17-4-10
Abstract
Objective: to study the effectiveness of leukotriene receptor antagonists in the treatment foratopic pathology in children.
Material and methods. 224 children with allergic diseases were prescribed to take montelucast for 3– 6 months.
Results. Taking montelucast has lead to positive clinical dynamics in 75 % of the cases.A significant reduction of the eosinophil count was achieved on days 10–15 of the therapy. The Cys-LTC4/D4/E4 indices came to normal after a one-month course of montelucast therapy in 40.3 % of cases in children with bronchial asthma, in 63.3 % of cases in children with allergic rhinitis and in 60.5 % of cases in children with atopic dermatitis.
Conclusions. The use of montelucast has significantly enhanced the control incidencerate ofallergic diseases in children.
About the Authors
A. I. Zariankina
Gomel State Medical University
Belarus
Belarus
Alla I. Zariankina — Candidate of Medical Science, Associate Professor, Head of the Department of Pediatrics of the EI «Gomel State Medical University»
M. Kh. Mirrakhimova
Tashkent Medical Academy
Uzbekistan
Uzbekistan
Maktuba KH. Mirrakhimova — Candidate of Medical Science, Associate Professor at the Department of Pediatric Diseases-1, Tashkent Medical Academy
E. R. Shamsieva
Tashkent Medical Academy
Uzbekistan
Uzbekistan
Eleonora R. Shamsieva — Candidate of Medical Science, Senior Lecturer at the Department of Pediatric Diseases1, Tashkent Medical Academy
References
1. Brytkova ТА, Kаzarin DD. Megdunarodniye rekomendacii po dyagnostyke i lecheniyu bronchialnoy astmy u detey v realnoy klinicheskoy praktike. Sovremenniye Tendencii Razvitiya Nauki i Technologiy. 2016;12:6-8. (in Russ.)
2. Nacionalnaya programma "Bronchyalnaya astma u detey. Strategiya lecheniya i profilactica". Moskva, RF: Oryginal-maket; 2017. 160 p. (in Russ.)
3. Nenasheva NM. Rol antileykotrienovych preparatov v dostigenii kontrolya bronchyalnoy astmy. Medicinskiy Sovet. 2017;8:44-49. (in Russ.)
4. Tichonova NK, Litvienko SN, Tichonov VG. Opyt profilacticheskogo primeneniya prolongirovannych kursov montelukasta u detey gruppy riska po vozniknoveniyu bronchialnoy astmy. Vestnyk Smolenskoy Gosudarstvennoy Medicinskoy Аkademii. 2019;18(3):241-46. (in Russ.)
5. Chalmatova BT, Myrrachimova MCH, Olmosov R. Oeffectivnost prymeneniya antagonistov leikotrienovych receptorov u detey s bronchialnoy astmoy. Symvol Nauki. 2017;5:25-31. (in Russ.)
6. Hammer SC, Sonneveld LH. Introduction of a new paediatric asthma guideline: Effects on asthma control levels. Pediatr Allergy Immunol. 2017;28: 266-72. https://pubmed.ncbi.nlm.nih.gov/28107572/
7. Klok T, Kaptein AA, Brand PP. Non‐adherence in children with asthma reviewed. Pediatric Allergy Immunology. 2015;26:197-205. https://pubmed.ncbi.nlm.nih.gov/25704083/
8. Pal K. et al. Leukotriene A4 hydrolase activation and leukotriene B4 production by eosinophils in severe asthma. American Journal of Respiratory Cell and Molecular Biology. 2019;60(4):413-19.
9. Gruzieva O. et al. Traffic-related air pollution and development of allergic sensitization in children during the first 8 years of life. Georgian Med News. 2014 Jun; 231:55-95. https://pubmed.ncbi.nlm.nih.gov/22104609/
10. Yamamoto T. et al. Current state and future prospect of the therapeutic strategy targeting cysteinyl leukotriene metabolism in asthma. Respiratory Investigation. 2019. https://pubmed.ncbi.nlm.nih.gov/31591069/
Review
For citations:
Zariankina A.I., Mirrakhimova M.Kh., Shamsieva E.R. Effectiveness of leukotriene receptor antagonists in the treatment for atopic pathology in children. Health and Ecology Issues. 2020;(4):38–42. (In Russ.) https://doi.org/10.51523/2708-6011.2020-17-4-10
Views: 571
Email this article 